Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma-Reference-Cited by-同舟云学术

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Published:2018-06 Issue:6 Volume:24 Page:749-757
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

McDermott David F.,Huseni Mahrukh A.,Atkins Michael B.,Motzer Robert J.,Rini Brian I.,Escudier Bernard,Fong Lawrence,Joseph Richard W.,Pal Sumanta K.,Reeves James A.,Sznol Mario,Hainsworth John,Rathmell W. Kimryn,Stadler Walter M.,Hutson Thomas,Gore Martin E.,Ravaud Alain,Bracarda Sergio,Suárez Cristina,Danielli Riccardo,Gruenwald Viktor,Choueiri Toni K.,Nickles Dorothee,Jhunjhunwala Suchit,Piault-Louis Elisabeth,Thobhani Alpa,Qiu Jiaheng,Chen Daniel S.,Hegde Priti S.,Schiff Christina,Fine Gregg D.,Powles Thomas

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0053-3.pdf

Reference64 articles.

1. Kaelin, W. G. Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14, 2703–2711 (2003).

2. George, D. J. & Kaelin, W. G. Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. 349, 419–421 (2003).

3. Motzer, R. J. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J. Clin. Oncol. 31, 3791–3799 (2013).

4. Clark, J. I. et al. Impact of sequencing targeted therapies with high-dose interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational Il-2 clinical trial: PROCLAIMSM. Clin. Genitourin. Cancer 15, 31–41.e4 (2017).

5. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

Cited by 962 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Advances in Vaccines for Melanoma;Hematology/Oncology Clinics of North America;2024-10

3. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study);International Journal of Cancer;2024-09-07

4. TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma;Frontiers in Immunology;2024-09-05

5. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors;Cellular Oncology;2024-09-02